Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

HIV Vaccine Rationale, Design and Testing

Author(s): Robert E. Sealy, Julia L. Hurwitz, Louis N. Martin, James L. Blanchard, Peter C. Doherty, Pamela J. Freiden, Timothy D. Lockey, Brita Brown, John Stambas, Karen S. Slobod, Bart G. Jones, Amy Zirkel, Sherri Surman, Xiaoyan Zhan, Scott A. Brown, Mattia Bonsignori and Chris Coleclough

Volume 3, Issue 2, 2005

Page: [107 - 112] Pages: 6

DOI: 10.2174/1570162053506928

Price: $65

Abstract

A central obstacle to the design of a global HIV vaccine is viral diversity. Antigenic differences in envelope proteins result in distinct HIV serotypes, operationally defined such that antibodies raised against envelope molecules from one serotype will not bind envelope molecules from a different serotype. The existence of serotypes has presented a similar challenge to vaccine development against other pathogens. In such cases, antigenic diversity has been addressed by vaccine design. For example, the poliovirus vaccine includes three serotypes of poliovirus, and Pneumovax(ρ) presents a cocktail of 23 pneumococcal variants to the immune system. It is likely that a successful vaccine for HIV must also comprise a cocktail of antigens. Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific Bcell and T-cell responses, are reviewed.

Keywords: hiv envelope protein, cocktail, breadth

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy